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SUMMARY
Growth factor (GF) deprivation and/or blocking of cognate signaling can induce apoptosis and is the basis of
several cancer treatment paradigms. We observed that RXR agonists (rexinoids) induce apoptosis of tumor
cells when GF support is abrogated. This ‘‘rexinoid apoptosis’’ involves activation of both iNOS and eNOS by
RXR-PPARg and results in production of apoptogenic NO. IGF/EGF-induced IGF receptor 1-mediated MAP
kinase blocks rexinoid apoptosis by RXR phosphorylation. Combining rexinoids with the MAPK inhibitor
U0126 induced apoptosis in human cancer cells in vitro and ex vivo and blocked xenograft growth in vivo.
Our results suggest a regulatory mechanism in which GF signaling antagonizes RXR-PPARg-mediated
default apoptosis to sustain cell life.INTRODUCTION
Retinoids bind to heterodimers composed of retinoic acid
(RARa, b, or g) and retinoid X receptors (RXRa, b, or g) and
initiate the sequence of events leading to transcription activation
by inducing allosteric alterations in a network of energetically
coupled residues that ultimately alter the structure of interaction
surfaces with secondary effectors, such as coregulators (de Lera
et al., 2007; Shulman et al., 2004). In the absence of ligand, RXR-
RAR heterodimers interact with corepressor complexes, which
are released upon RAR agonist binding, thus allowing recruit-
ment of coactivator complexes and the transcriptional ma-
chinery. Depending on RAR isotype, cell, and target gene con-
texts, RXR-selective agonists (‘‘rexinoids’’) alone are generally
unable to dissociate corepressor and activate transcription,
a phenomenon referred to as ‘‘RXR subordination,’’ but a rexi-220 Cancer Cell 16, 220–231, September 8, 2009 ª2009 Elsevier Innoid can synergize with a retinoid to enhance the RXR-RAR-
mediated transcription through cooperative recruitment of coac-
tivators (Germain et al., 2002). RXRs can additionally heterodi-
merize with a variety of other nuclear receptors, such as PPARs,
VDR, TR, or orphan receptors. In RXR-VDR or RXR-TR, RXR is
subordinated to its partner, but in permissive heterodimers,
such as PPAR-RXR, transcription can be activated by rexinoids
autonomously (for a recent review and references, see de Lera
et al., 2007).
Data from cellular and animal models and clinical trials reveal
a potent antitumor activity of rexinoids, which are less toxic than
retinoids, thus favoring their use in the clinic (for a recent review
and references, see Altucci et al., 2007). Indeed, the selective
RXR agonist LG1069 (targretin, bexarotene) is currently used
as treatment for persistent or refractory cutaneous T cell lym-
phoma. Moreover, recently completed phase 3 clinical trialsSIGNIFICANCE
In animals, tissue homeostasis is attained by the balance between cellular proliferation, survival, and death. Cancer results
from deregulated growth, often caused by (epi)genetic alterations of GF signaling networks and/or pathways that ensure
apoptogenic eradication of aberrant growth. We describe here in mechanistic detail that growth factor (IGFs and EGF)
signaling is necessary for survival of leukemic and solid cancer cells in culture, if RXR-PPARg signaling is switched on.
Indeed, the combination of rexinoids with compounds that block GF action induces cell death in vitro and dramatically
inhibits growth of xenografts in vivo. The GF-rexinoid antagonism is likely of relevance for organogenesis and tissue regen-
eration and may be exploited for cancer therapeutic and preventive strategies.c.
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group of patients with non-small-cell lung cancer may benefit
from the addition of bexarotene to the therapeutic scheme (Blu-
menschein et al., 2008; Ramlau et al., 2008). In addition, studies
with transgenic MMTV-erbB2 and A/J mouse carcinogenesis
models have revealed the potential of rexinoids to prevent
cancer in both lung and mammary gland (Li et al., 2007; Liby
et al., 2007a; Liby et al., 2007b). Finally, RXR is a therapeutic
target for acute promyelocytic leukemias because of the
suppression of RARa fusion-mediated transformation, possibly
as consequence of rexinoid-induced apoptosis (Zeisig et al.,
2007).
We have previously studied signaling pathways by which
rexinoids can act despite the subordination of its receptor and
have uncovered two distinct mechanisms. One involves the in-
duction of differentiation and postmaturation apoptosis of acute
promyelocytic leukemia (APL) cells in the presence of elevated
cAMP levels (Benoit et al., 1999). This rexinoid-cAMP synergy
was operative even in all-trans retinoic acid (ATRA)-resistant
APL cells, indicating a mechanism of action distinct from that
of retinoids. Indeed, increased cAMP levels result in ‘‘desubordi-
nation’’ of RXR in the RXR-RAR heterodimer, thus activating
gene programs that synergize with cAMP-dependent programs
to induce acute myeloid leukemia (AML) blast differentiation
and apoptosis. Interestingly, apoptosis is induced in cells un-
responsive to ATRA and involves the simultaneous induction
of the tumor-selective TNF-related apoptosis-inducing ligand
(TRAIL) and its cognate receptor (Altucci et al., 2005).
The second signaling option was discovered when growth
factor support of AML cells growing in the presence of a rexinoid
was lowered by decreasing the serum concentration. Under
such conditions, the rexinoid alone induced rapid cell death,
referred to as ‘‘autonomous rexinoid apoptosis,’’ because it
did not involve coactivation of other pathways and resulted in
apoptosis without differentiation (Benoit et al., 2001). Notably,
this signaling paradigm also is active in non-APL AML patient
blasts.
Although there are divergent reports from mouse genetic anal-
yses on the possibility that PPARg may act in some tissues as
tumor suppressor (McAlpine et al., 2006; Saez et al., 2003), there
is no controversy regarding the antiproliferative capacity of the
activated RXR-PPARg heterodimer against a great number of
transformed cells and the potential of cognate agonists for adju-
vant and chemopreventive cancer therapy (Elrod and Sun, 2008).
The present work was initiated to decipher the mechanistic basis
of autonomous rexinoid apoptosis (Benoit et al., 2001).
RESULTS
Rexinoid Apoptosis Involves Activation of Intrinsic
Death Pathway
Although RXR agonists did not affect growth or differentiation of
myeloid PLB985 cells in normal culture conditions, cells adapted
to growth in low serum undergo rapid and massive apoptosis
upon exposure to the rexinoid BMS749; under identical condi-
tions, the RARa-selective agonist BMS753 was completely inac-
tive (Figure 1A). To assess the contributions of the extrinsic and
intrinsic death pathways (Debatin, 2004) to rexinoid apoptosis,
the activation of caspases and the effect of caspase inhibitorsCwere assessed. Under apoptogenic (low serum) conditions, rexi-
noids rapidly activated pro-caspase 9, accompanied by activa-
tion of caspase 3 and PARP cleavage (Figure 1B). Pro-caspase
8 activation was observed with similar kinetics. Selective inhibi-
tors of caspase 8 and 10 decreased cell death by about 20%
each but did not block it completely (Figure 1C). Cleavage of
proapoptotic Bid indicated that the two apoptotic pathways
are connected. Together, these data revealed a contribution of
both the intrinsic and extrinsic pathways to rexinoid-induced
cell death.
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Figure 1. The Rexinoid BMS749 Induces Caspase-Dependent
PLB985 Cell Apoptosis
(A) BMS749 induces a dose-dependent apoptosis, whereas the RARa agonist
BMS753 has no effect. Cells were treated for 24 hr as indicated, apoptosis was
revealed by Apo2.7 staining. Right panel, FACScan of Apo2.7 staining.
(B) Rexinoid treatment induces the cleavage of casp-3, 9, and 8; PARP; and
Bid as shown by western blotting. Full length (FL) and cleaved fragments are
indicated.
(C) Caspase inhibitors reduce BMS749-induced apoptosis. PLB985 cells were
pretreated for 2 hr with 100 mM Z-VAD-FMK, Z-IETD-FMK, and Z-AEVD-FMK
or combinations prior to addition of BMS749. After 48 hr, the sub-G1 fractions
representing apoptotic bodies were analyzed by PI staining and FACS anal-
ysis. Bars represent the mean ± SD.ancer Cell 16, 220–231, September 8, 2009 ª2009 Elsevier Inc. 221
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Growth Factor-Antagonized Rexinoid ApoptosisRNase protection assays showed a moderate induction of
DR5 but no regulation of FasL, TNFa, or their cognate receptors
by rexinoids (Figure 2A). Although TRAIL expression decreased
upon rexinoid treatment, its cognate receptor DR5 was strongly
overexpressed (Figure 2B). To assess whether DR5 signaling
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Figure 2. The Death Receptor Pathway Contributes to Rexinoid-
Induced Apoptosis
(A) RPA analysis of PLB985 treated with BMS749 is depicted.
(B) Western blot analysis of TRAIL and DR5 protein expression. PLB985 cells
were treated as indicated. The nonspecific band (NS) confirms equal loading.
(C and D) PLB985 lines stably expressing a GFP-tagged dominant-negative
FADD (GFP-FADDdn) or a b-galactosidase (LacZ) were generated by lentiviral
tranduction. Expression of the fusion protein was verified by western blot (C) or
FACS analysis (D).
(E) PLB985 cells expressing the GFP-FADDdn protein are less sensitive to re-
xinoid-induced apoptosis. WT, Lac Z, or GFP-FADDdn PLB985 were treated
for 24 hr with BMS749. TRAIL (20 ng/ml) was used to validate the FADD domi-
nant-negative effect. Staurosporine (STS, 100 nM) and CCCP (2 mM) target the
mitochondrial apoptotic pathway and were used as negative control.
(F) Deletion of DR5 reduces rexinoid apoptosis. BJAB and DR5-deficient BJAB
cells were subjected to rexinoid apoptosis (BMS749 and U0126, see text), and
apoptosis was measured. Bars represent the mean ± SD of percentage of
7A6-positive cells.222 Cancer Cell 16, 220–231, September 8, 2009 ª2009 Elsevier Inccontributes to rexinoid apoptosis, we transduced a lentiviral
dominant-negative FADD fused to GFP (GFP-FADDdn) or
b-galactosidase (LacZ) into PLB985. Immunoblotting (Figure 2C)
confirmed transgene expression, and FACS analysis of GFP
fluorescence revealed that 98% of the cells were infected
(Figure 2D). Sensitivity to apoptosis induced by exogenous
TRAIL was strongly reduced and close to control levels in
GFP-FADDdn but not in wild-type (WT) or LacZ cells, thus dem-
onstrating that the death receptor pathway is effectively inhibited
in these cells (Figure 2E). As expected, staurosporine and CCCP,
two drugs that target the mitochondrial death pathway, induced
apoptosis with the same efficiency in the various cell lines
(Figure 2E). That rexinoid BMS749-induced cell death was about
20% to 25% lower in GFP-FADDdn than in WT or LacZ cells in-
dicates a contribution, albeit not a critical one, of the death
receptor signaling to rexinoid-induced apoptosis. In support of
this conclusion, DR5-deficient BJAB cells (Thomas et al., 2004)
exhibited reduced rexinoid apoptosis, compared with parental
BJAB, but still retained significant susceptibility (Figure 2F).
Activation of the intrinsic pathway is initiated by permeabiliza-
tion of the outer mitochondrial membrane, resulting in a loss of
transmembrane potential (DJm) (Green and Kroemer, 2004).
Indeed, rexinoids induce a loss of DJm, as demonstrated by
DiOC6 staining (Figure 3A) and the release of proapoptotic mito-
chondrial cytochrome c and Smac/Diablo in the cytoplasm 2–3
hr after rexinoid exposure (Figure 3B). To validate the critical
involvement of the intrinsic death pathway in rexinoid-induced
apoptosis, we generated cells stably expressing Bcl-2 and GFP
or only GFP from bicistronic vectors. Immunoblotting (Fig-
ure 3C) and FACS analysis of GFP fluorescence (Figure 3D)
confirmed transgene expression. Notably, the sensitivity to rexi-
noids (‘‘BMS749’’) as well as staurosporine (‘‘STS’’) is dramati-
cally reduced in Bcl-2-overexpressing cells, compared with
WT or vector (pIRES)-nucleofected cells, demonstrating a domi-
nant contribution of mitochondrial-dependent apoptosis in rexi-
noid-induced cell death (Figure 3E).
Rexinoid-Induced Nitric Oxide Production Is Required
for Apoptosis
Death by mitochondrial damage and concomitant loss of
membrane potential can be caused by multiple intracellular
events, including the generation of reactive oxygen species
(ROS) or nitric oxide (NO). In assaying multiple pathways, we de-
tected the production of NO in BMS749-treated PLB985 cells
(Figure 4A, left panel) and confirmed by DAF-FM staining (Fig-
ure 4A, right panel) the presence of increased levels of cyto-
plasmic NO in the treated cells. NO production was similarly
observed in BJAB and DR5-deficient BJAB cells (data not
shown). This induction was blocked by L-NMMA, a pan-NO syn-
thase inhibitor (Figures 4B and 4C). Interestingly, the kinetics of
NO production correlated with that of cytochrome c release
(Figure 3B). In keeping with the observation that NO can activate
the mitochondrial apoptosis pathway (Brune, 2003), L-NMMA
decreased rexinoid apoptosis by 60% (Figure 4C) and abrogated
cytochrome c release (Figure 4D). Inhibitors of ROS, L-NAC, and
GSH failed to inhibit rexinoid apoptosis, indicating that only NO is
involved in this process (Figures 4C and 4D).
Two main types of synthases are involved in the production of
NO in normal cells: inducible NO synthase (iNOS) and endothelial.
Cancer Cell
Growth Factor-Antagonized Rexinoid ApoptosisNO synthase (eNOS). iNOS generally produces a rapid and large
burst of NO, whereas eNOS, a constitutive enzyme, is involved in
maintenance of NO levels. Western blot analysis revealed strong
iNOS induction within 1 hr of BMS749 exposure, while eNOS
levels remained unchanged (Figure 4E). However, phosphoryla-
tion of specific residues of eNOS has been shown to modulate
the activity of the enzyme; in particular, Ser1177 phosphorylation
has been demonstrated to be an important positive regulator.
Indeed, BMS749 induced within 2 hr the levels of pSer1177
eNOS, and RNAi-mediated knockdown confirmed the critical
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Figure 3. Involvement of the Mitochondrial Death Pathway in Rexi-
noid-Induced Apoptosis
(A) BMS749 induces loss of mitochondrial transmembrane potential. PLB985
cells were treated for 24 hr with 1 mM BMS749 and analyzed for DiOC6 uptake.
(B) Western blot analysis of cytochrome c and Smac/Diablo release. Cells were
treated with BMS749, as indicated, and mitochondrial and cytoplasmic
proteins were analyzed.
(C and D) PLB985 cells were stably transfected with pIRES EGFP or pIRES
Bcl-2 EGFP vectors. Western blot for Bcl-2 (C) and FACS analysis for GFP
(D) confirmed expression of the transgenes.
(E) Bcl-2 overexpression decreases rexinoid-induced apoptosis. WT, pIRES,
or pIRES Bcl-2 GFP expressing cells were treated as indicated. Bars repre-
sented percentage of 7A6-positive cells (mean ± SD).Cinvolvement of both NOSs in rexinoid apoptosis, because deple-
tion of either NOS significantly decreased the apoptosis (Fig-
ure 4F; note that a combination of both siRNAs proved to be
lethal and could not be tested). Together, these data suggest
that a synergy between the two NOSs results in a large and sus-
tained increase of NO levels.
Because DR5 is a target of p53, we wondered whether its
induction by the rexinoid was mediated by NO-activated p53,
thereby linking the intrinsic with the extrinsic death pathway.
Indeed, upon rexinoid exposure, a strong increase of p53-acti-
vating phophorylation at serine 15 was observed (Figure 4G) in
PLB985 and BJAB cells, and this phosphorylation was inhibited
by L-NMMA, revealing the involvement of NO. As expected from
these results, retroviral transduction of p53 shRNA reduced rexi-
noid apoptosis in BJAB cells (data not shown). Together, these
results demonstrate that both the extrinsic and intrinsic path-
ways execute rexinoid apoptosis.
IGF Receptor I Activation Antagonizes
Rexinoid-Apoptosis
That PLB985 or NB4 cells maintained under normal serum
conditions do not exhibit any apoptotic response to rexinoids
and that progressive increase in the serum concentration in-
hibited rexinoid apoptosis (Figure 5A) (Benoit et al., 2001)
prompted us to investigate the possible contribution of growth
factor signaling to this antagonism. Of a battery of growth factors
and cytokines, only IGF1, IGFII, and EGF antagonized rexinoid
apoptosis under low serum conditions (Figure 5B; data not
shown). Importantly, the addition of IGFs (1 and II) also inhibited
NO induction, whereas depletion of residual IGFs in the medium
by neutralizing antibodies significantly enhanced this process
(Figure 5C) and subsequent apoptosis (data not shown). More-
over, IGFs also blocked cytochrome c release (Figure 5D).
Note that apoptosis induced by TRAIL (extrinsic death pathway)
or etoposide (intrinsic death pathway) was not rescued by these
growth factors (see Figure S1A available with this article online).
These results confirm the ability of growth factors to selectively
counteract apoptosis proceeding along the rexinoid-NO sig-
naling axis.
Analysis of the signaling cascades triggered by these growth
factors identified MAP kinase activation as a cause of the block
of rexinoid apoptosis. Indeed, the MEK1/2 inhibitor U0126 com-
pletely blocked EGF- or IGF-mediated survival, whereas p38
MAP kinase (SB) or PI3 kinase (LY) inhibitors were ineffective
(Figure 5E). In keeping with these results, the addition of EGF
to the culture medium induced a rapid and sustained phosphor-
ylation of the MEK1/2 substrate p42/44 MAP kinase, as shown
by western blot analysis (Figure 5F). The induction of p42/44
activity by IGF1, EGF, and FCS was confirmed by in vitro kinase
assays using Elk-1 as substrate (Figure 5G). No significant
changes were observed in the phosphorylation status of p38 or
Akt (Figure S1B).
Although IGF receptor 1 (IGFR1) is well expressed, in agree-
ment with previous observations (Chen et al., 1993; Stegmaier
et al., 2005), no EGF receptor could be detected in PLB985.
Notably, both IGF1 and EGF, as well as FCS, stimulated IGFR1
autophosphorylation (Figure 6A) and Elk1 phosphorylation (Fig-
ure 6B). Moreover, the IGFR1 tyrosine kinase inhibitor AG1024
antagonized IGF1 as well as EGF-induced survival, whereasancer Cell 16, 220–231, September 8, 2009 ª2009 Elsevier Inc. 223
Cancer Cell
Growth Factor-Antagonized Rexinoid Apoptosisthe EGFR inhibitor AG1478 had no effect (Figures 6C and 6D).
Thus, as it was observed for hepatocytes (Hallak et al., 2002),
EGF operates in PLB958 cells through IGFR1. The MEK/p42/
44 MAPK pathway thus acts upstream of the NO production
step to mediate the antiapoptotic action of IGFs and EGF
against rexinoid-induced cell death. Note that, although the
rexinoid was ineffective in presence of 10% FCS, addition of
the MEK1/2 inhibitor U0126 turned it into a powerful death
inducer (Figure 5H); this permits the study of rexinoid apoptosis
under culture conditions without the need to adapt cells to low
serum.
Rexinoid-Induced Apoptosis Is Mediated by the RXR-
PPARg Heterodimer and Is Blocked by Growth Factor-
Mediated RXRaS260 Phosphorylation
By screening a panel of ligands for multiple permissive and
nonpermissive RXR complexes, we observed that the PPARg
agonist troglitazone (TZD) induced PLB985 apoptosis. Impor-
tantly, apoptosis occurred under the exact conditions of rexinoid
apoptosis—that is, when serum concentration is limiting (Fig-
ure 7A). Indeed, the pattern of caspase activation, NO produc-
tion, and cytochrome c release was indistinguishable from
that seen with rexinoids (Figures S2A–S2C). PPARg agonists tro-
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Figure 4. Nitric Oxide (NO) Production Is
Required for Rexinoid Apoptosis
(A) Time course of NO production in PLB985 cells
treated with BMS749, depicted as mean ± SD of
percentage of DAF-positive cells. Right hand panel
shows staining of cells with DAF-FM; fluorescence
is produced as a result of DAF-FM interaction with
NO. Scale bar, 10 mm.
(B) FACScan analysis reveals NO production. Cells
were pretreated or not with 500 mM of NOS inhib-
itor L-NMMA, exposed for 2 hr to BMS749, and
prepared for flow cytometry.
(C) NOS inhibitor decreases rexinoid apoptosis.
PLB985 cells were pretreated for 2 hr with
L-NMMA (200 and 500 mM), GSH, or L-NAC (1
and 5 mM) before BMS749 treatment for 24 hr.
(D) NO production induces cytochrome c release.
PLB985 cells were pretreated for 2 hr with
L-NMMA (200 and 500 mM), or 2 mM GSH, or
L-NAC. BMS749 was added for 4 hr before har-
vesting the cells.
(E) BMS749 induces iNOS and the phosphoryla-
tion of eNOS.
(F) PLB985 transfected with eNOS- and iNOS-
specific siRNA were exposed to BMS749. Apo-
ptosis in (C) and (F) was assessed by FACScan
detection of Apo2.7 staining.
(G) BMS749 activates p53 in PLB985 and BJAB
cells as detected by western blot of Ser15 phos-
phorylation, which is blocked by treatment with
L-NMMA. Bars represent the mean ± SD of
percentage of 7A6-positive cells.
glitazone and 15-deoxy-D-12,14-prosta-
glandin J2 (15d-PGJ2) synergized with
various rexinoids for apoptosis induction,
whereas no effect was seen with PPARa
(WY) or PPARb (BMS990) agonists (Fig-
ures 7A and 7B), thus revealing the specific involvement of
RXR-PPARg heterodimers. As expected, the addition of rexi-
noids enhanced TZD-induced apoptosis, which was attenuated
by IGF1, EGF, and FCS (Figure S2D). Finally, siRNA-mediated
depletion of either PPARg or RXR demonstrated their critical
implication in both NO production (Figure 7C) and apoptosis
(Figure 7D). RNA interference confirmed that RXRPPARg het-
erodimers are required for eNOS phosphorylation (Figure 7E),
and chromatin immunoprecipitation revealed PPARg and RXR
binding to a region 1 kb upstream of the transcriptional start
site (TSS) of NOS2A, leading to RNA polymerase II recruitment
at the TSS (Figure 7F). No such binding or polymerase recruit-
ment was seen to a region 6 kb upstream. Taken together, these
data fully support a model in which the permissive RXR-PPARg
heterodimer mediates the rexinoid signal, which activates the
intrinsic death pathway though NO production.
A number of RXR and PPARg phosphorylation sites have been
identified previously, but only PPARgS112 and RXRaS260 are
substrates for ERK1/2. Most importantly, phosphorylation of
RXRaS260 has been linked to attenuated ligand responsiveness
to several nuclear receptor heterodimers in ras-transformed cells
as a result of impaired coactivator recruitment and repression of
the transactivation capacity (Macoritto et al., 2008); in colorectal224 Cancer Cell 16, 220–231, September 8, 2009 ª2009 Elsevier Inc.
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Growth Factor-Antagonized Rexinoid Apoptosiscancer, RXRaS260 phosphorylation impairs the antiproliferative
response to thiazolidinediones and RXR ligands (Yamazaki
et al., 2007), and differential ubiquitin/proteasome-dependent
degradation in normal hepatocytes and hepatocellular carci-
noma was reported to originate from differential RXRaS260 phos-
phorylation (Adachi et al., 2002). In the case of PPARg2, phos-
phorylation of S112 (S84 in PPARg1) leads to a predisposition to
sumoylation of K107 and confers strong repression activity on
the receptor (Adams et al., 1997; Yamashita et al., 2004).
To assess whether the antagonistic affect of growth factor/
serum-stimulation on rexinoid apoptosis could be mediated by
MAPK phosphorylation of (one of) these residues, the impact
of the corresponding mutation on NO production was deter-
mined. Although transient overexpression of PPARg2S112A and
PPARg2K107R mutants increased the basal level of number of
NO-positive cells, none of the mutants prevented serum from
inhibiting NO production (Figure 7G). In striking contrast, the
expression of RXRaS260A completely abrogated the serum
effect, revealing that serum-induced MAPK activation targets
this residue to prevent the production of NO and, thus, rexinoid
apoptosis.
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Figure 5. IGFI, IGFII, and EGF Rescue
PLB985 from Rexinoid Apoptosis
(A) Serum factors inhibit rexinoid-induced death.
Cells treated for 24 hr with BMS749 and increasing
amounts of serum were assayed for apoptosis.
(B) PLB985 were cotreated with BMS749 and
1 mg/ml of the indicated growth factors; 48 hr later,
apoptosis was measured.
(C) Blocking IGF signaling by IGF neutralizing anti-
bodies (anti-IGF) increases NO production.
(D) EGF and IGF1 inhibit apoptosis by blocking
cytochrome c release. PLB985 cells were pre-
treated for 2 hr with EGF and IGFI and exposed
for 4 hr to BMS749.
(E) MEK1/2 inhibition reverses EGF-induced sur-
vival. PLB985 cells were pretreated for 2 hr with
10 mM SB203580, 10 mM LY294002, and 5 mM
U0126. The cells were then exposed to a combina-
tion of BMS749 and EGF or IGF, and 24 hr later,
apoptosis was measured.
(F) Kinetics of p42/44 phosphorylation under EGF
exposure assessed by western blotting.
(G) In vitro kinase assay of p42/44 activity with
extracts of PLB985 treated or not for 1 hr with
IGFI, EGF, or 10% FCS. Elk-1 was used as p42/
44 target.
(H) NO production is blocked by growth factor
signaling. PLB985 cells were treated with IGF1,
10% FCS, or 10% FCS+U0126. Bars represent
the mean ± SD.
Growth Factor-Antagonized
RXR Apoptosis Is a General
Phenomenon in Different
Cell Types
It is tempting to speculate that rexinoid
apoptosis may correspond to a general
phenomenon that allows the eradication
of cells that are not growth factor-sup-
ported. Indeed, analysis of distinct cell
types supported this hypothesis. Within the hematopoietic line-
age, several cell lines displayed apoptogenic sensitivity toward
rexinoids exclusively in low serum (Figure 8A; data not shown).
In cases where adaptation to low serum was possible, primary
blast cultures obtained from patients with acute myeloid leu-
kemia showed dramatic apoptosis when rexinoid, low serum,
and MAP kinase inhibitors were combined (Figure 8B). Note
that the extent of death was similar to that seen with HDAC inhib-
itors MS275 and SAHA. Also, nonhematopoietic cell lines,
including SKBR3, MCF7, and ZR75 breast cancer and HCT116
and HT29 colon cancer cell lines, displayed rexinoid apoptosis
(Figures 8C and 8D; data not shown). In the case of SKBR3, addi-
tional blocking of HER2 signaling by gefinitib (IRESSA) strongly
enhanced apoptosis, which was sensitive to the NOS inhibitor
L-NMMA, thus supporting the implication of NO signaling
(Figure 8C; data not shown).
Anticancer Action of Rexinoid Apoptosis In Vivo
To assess antitumor efficacy of rexinoid apoptosis in vivo, we
treated nude mice bearing HCT116 tumor xenografts with
BMS749 alone and in combination with U0126 for 2 weeks.Cancer Cell 16, 220–231, September 8, 2009 ª2009 Elsevier Inc. 225
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Figure 6. p42/44 MAP Kinase Pathway
Mediates the Survival Signal Counteracting
Rexinoid Apoptosis Through IGFRI Activa-
tion
(A) Growth factors enhance autophosphorylation
of IGF-1R. Extracts of PLB985 cells treated for 1 hr
with IGF1, EGF, or FCS were immunoprecipitated
with anti-phosphoIGF1R antibody. Nonphos-
phorylated IGF1R is depicted above.
(B) p42/44 kinase assays with protein extracts
of PLB985 treated as indicated (U0126, 5 mM;
AG1024, 2 mM). Elk1 was used as p42/44 sub-
strate.
(C) PLB985 pretreated with the tyrosine kinase
inhibitors AG1024 or AG1478 were exposed to
BMS749 in combination or not with EGF or IGFI
and subjected to apoptosis analysis.
(D) FCS-mediated survival involves IGFRI and
p42/44 activation. PLB985 pretreated for 2 hr
with 10 mM U0126, 10 mM LY294002 (LY), 10 mM
SB203580 (SB), or 2 mM AG1024 or AG1478
were exposed for 48 hr to BMS749 combined or
not with 10% FCS, and apoptosis was measured.
Bars represent the mean ± SD.Using 20 mpk BMS749 and 30 mpk U0126, we did not observe
any toxicity, as supported by the normalized weight profile
(Figure S3). Although BMS749 and U0126 alone had a moderate
effect of tumor growth (21% ± 13% and 44% ± 10% growth inhi-
bition, respectively), their combination dramatically impaired
tumor cell expansion in vivo (83% ± 7%; see Figures 8E and
8F). Using luciferase-expressing HCT116, the combined treat-
ment halted tumor growth in the first week of treatment nearly
quantitatively (Figure 8G). These results indicate that the combi-
nation of rexinoids with agents that interfere with growth factor
signaling may correspond to an efficient cancer-therapeutic
paradigm.
DISCUSSION
The anticancer activity of retinoids is well established, and the
induction of differentiation and/or apoptosis is a hallmark of
this therapeutic potential (Altucci and Gronemeyer, 2001; Altucci
et al., 2007). Clinical studies and experiments with the Ptch1+/
mouse model indicate that retinoids can also act in a cancer-
preventive manner in the cases of basal cell carcinoma (Orlandi
et al., 2004; So et al., 2004) and oral cancers (Lippman et al.,
2005). Retinoids act through binding to RAR in RAR-RXR heter-
odimers, but RXR is a promiscuous heterodimerization partner
for multiple nuclear receptors.
Rexinoids, synthetic RXR-selective ligands (de Lera et al.,
2007), display lower toxicity than retinoids do and are increas-
ingly recognized for their cancer therapeutic and preventive
potential (Altucci et al., 2007; Gottardis et al., 1996). Rexinoids
have caught significant attention as recent molecular and mouse
genetic studies continue to provide mechanistic insight. The
observations that epidermis-selective RXRa and/or RXRb abla-
tion generates hyperplasia and hyperkeratinization and that
RXRa-PPARg heterodimers can act as suppressors of chemi-
cally induced epidermal tumorigenesis (Indra et al., 2007; Oca-
diz-Delgado et al., 2008) emphasize the importance of RXRs226 Cancer Cell 16, 220–231, September 8, 2009 ª2009 Elsevier Incas anticancer drug targets. Although RXR is ‘‘subordinated’’ to
RAR in the corresponding heterodimer (Germain et al., 2002), re-
xinoids have several options to exert activity in the absence of
retinoids. First, they can cross-talk with other pathways to ‘‘acti-
vate’’ RAR-RXR; this option has promise as therapeutic ap-
proach for AML. Indeed, the cross-talk between cAMP and rexi-
noids allows to target the majority of AML cases (Altucci et al.,
2005), while retinoic acid-based ‘‘differentiation therapy’’ is
limited to APL. Second, rexinoids activate ‘‘permissive’’ RXR
heterodimers (Shulman et al., 2004), such as RXR-PPARg;
finally, they interfere with oncogenic transformation by aberrant
RAR fusion proteins (Zeisig et al., 2007).
Here, we report a fourth anticancer signaling option for rexi-
noids, the growth factor-antagonized induction of ‘‘rexinoid
apoptosis’’ (Benoit et al., 2001) mediated by the putative tumor
suppressor PPARg-RXR (Indra et al., 2007) through NO-depen-
dent activation of the intrinsic death pathway (Figure 8H), and
reveal its therapeutic potential in vitro, in leukemic blasts ex
vivo, and in xenograft assays in vivo. Rexinoid apoptosis in
absence of growth factor support is entirely different from the re-
xinoid-cAMP cross-talk mentioned above (Altucci et al., 2005),
because it (1) is not inhibited but is increased by RAR antago-
nists, (2) involves the RXR-PPARg permissive heterodimer, (3)
does not require prior differentiation, and (4) involves intrinsic
and extrinsic death pathways.
Conceptually, our results suggest the existence of a regulatory
paradigm by which a cell (compartment/tissue) that is dependent
on growth factor support, particularly IGFs or EGF (others remain
to be validated), will be eliminated by rexinoid apoptosis as soon
as GF support ceases. The beauty of this concept is that solely
the presence of GF (in cases of constant rexinoid levels) suffices
to promote survival, and its absence automatically leads to
death. Apart from GF modulation, this model implies the exis-
tence of endogenous RXR ligands, which may represent a
second trigger, allowing nonsupported cells to survive in ab-
sence of (sufficient) rexinoid. The existence of endogenous.
Cancer Cell
Growth Factor-Antagonized Rexinoid Apoptosisrexinoids has been reported elsewhere (de Urquiza et al., 2000;
Solomin et al., 1998), and data from RXR mutant mice add
credence to such concept. Indeed, interdigital webbing (syndac-
tyly) has been observed in RXR AF1 domain mutants and is an
accepted marker for an apoptotic defect leaving the interdigital
mesenchyme intact during embryonic development (Mascrez
et al., 2001). Therefore, it is possible that rexinoid apoptosis is
a general mechanism involved in tissue development, repair,
and homeostasis.
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Figure 7. Rexinoid Apoptosis Involves
RXRa-PPARg Heterodimer Binding to the
iNOS Promoter and Leads to eNOS Phos-
phorylation
(A) PLB985 cultured in 1% or 10% FCS were
treated for 24 hr with PPAR agonists as indicated,
and apoptosis was measured.
(B) PLB985 were exposed to four different rexi-
noids: SR11237 (SR; 1 mM), 9-cis RA (1 mM),
LG1069 (1 mM), and BMS749 (0.5 mM), in com-
bination with troglitazone (TZD) or 15-deoxy-
D(delta)12,14-prostaglandin J2 (15d-PGJ2). Apo-
ptosis analyses reveal synergistic action of PPARg
and RXR agonists.
(C and D) Inhibition of iNOS and eNOS by siRNA
reduces NO positivity (C) and apoptosis (D) in-
duced by BMS749.
(E) Phosphorylation of eNOS at S1177 is induced by
BMS749 and abrogated by knocking down RXRa
or PPARg.
(F) ChIP assays reveal ligand-induced binding of
PPARg and RXRa upstream of the iNOS promoter
and PolII to the transcription start site (TSS).
Assays were performed with HCT116 cells grown
in 0.5% serum. Ligands and/or FCS were added
for 1 hr. Data represent fold occupancy deter-
mined by real-time PCR of ChIPed DNA.
(G) RXRaS260 is targeted by growth factors while
phosphorylation-deficient PPARg mutants still
support serum-dependent suppression of NO-
mediated rexinoid apoptosis. Note that serum
does not antagonize NO production in cells ex-
pressing RXRaS260A. Bars represent the mean
± SD.
Our results reveal that the intrinsic
death pathway triggered by NO executes
rexinoid apoptosis. This finding is sup-
ported by the fact that the selective
NOS inhibitor L-NMMA dramatically de-
creases both rexinoid-induced NO pro-
duction and apoptosis. NO has been
described to induce phosphorylation and
activation of p53 (Brune, 2003; Schnei-
derhan et al., 2003), which leads to the
induction of DR5 (Wu et al., 1997), as
shown in Figure 4G. The role of NO in
the modulation of apoptosis is controver-
sial. The two main types of NOS are the
inducible (iNOS) and the endothelial
(eNOS) forms. iNOS has been shown to
rapidly and strongly induce the produc-
tion of NO during inflammatory responses, whereas eNOS has
been assigned the function of producing low amounts of NO
for basic cell homeostasis (Li and Wogan, 2005). The role of
eNOS as a protective agent has been demonstrated in endothe-
lial cells, where it is able to prevent TNFa, LPS, or ROS-induced
apoptosis (Dimmeler et al., 1997). However, this antiapoptotic
function seems to be restricted to endothelial cells and a few
other cell types. iNOS induction, and the resultant NO increase,
plays an important role in septic shock and has an apoptotic roleCancer Cell 16, 220–231, September 8, 2009 ª2009 Elsevier Inc. 227
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Figure 8. Rexinoid Apoptosis Operates in Different Cell Types In Vitro and In Vivo
(A) Apoptosis induced with BMS749 in hematopoietic cells cultured in 1% or 10% FCS.
(B) Rexinoid apoptosis assays with blasts of AML patient 104 cultured ex vivo. Blasts were cultured in 20% FCS or 1% FCS+HY.
(C) IRESSA potentiates rexinoid apoptosis of SKBR3 cells. Apoptosis of SKBR3 cells grown in 10% FCS and treated with BMS749, U0126, PGJ2, or IRESSA is
shown.
(D) Rexinoid apoptosis induced in HCT116 colon cancer cells.
(E) Efficient in vivo antitumor effect on HCT116 xenografts under conditions of rexinoid apoptosis. Xenografted nude mice were treated every other day with
vehicle or the indicated doses of BMS749, U0126, or both for 2 weeks. Photograph of mice at the end of the treatment is shown.
(F) Graphical representation of tumor weights (±SD) in xenografted mice.
(G) In vivo imaging of representative luciferase-tagged HCT116 xenografted mice imaged at the beginning and after 7 days of treatment. Tumor sizes quantified as
total amount of light emitted (photons/s) are given below the photos. Note the block of tumor growth by BMS749-U0126 cotreatment.
(H) Schematic representation of RXR-PPARg-mediated apoptosis in AML cells. Activation of RXR-PPARg heterodimers by RXR or PPARg agonists induces NO
production by iNOS and eNOS, which, in turn, affects mitochondria integrity and triggers cytochrome c release and apoptosome formation. This activation of the
intrinsic death pathway can be inhibited by Bcl-2 overexpression. Additionally, NO release activates p53, which leads to overexpression of DR5 that triggers an
amplification loop involving caspase 8 and Bid cleavage. The implicated extrinsic death pathway can be blocked at the DISC by dominant-negative FADD or DR5-
deficiency. IGF1-like growth factors activate through binding to IGFRI a MAPK survival pathway which attenuates rexinoid apoptosis by phosphorylating RXRa at
S260. In cells grown in serum growth factor, signaling can be blocked by IGFR1kinase inhibitors (AG1024) or downstream by MEK inhibition (U0126), thereby
facilitating rexinoid apoptosis in presence of growth factors. Bars indicate mean ± SD.in most cell types, including macrophages and monocytes.
Notably, in eNOS knockout mice, induction in iNOS activity
due to LPS was significantly diminished (Connelly et al., 2005).
A number of reports have demonstrated a role for PPARg in228 Cancer Cell 16, 220–231, September 8, 2009 ª2009 Elsevier Inthe phosphorylation of eNOS at S1177 and augmentation of its
activity. In fact, NO produced by eNOS has been shown to be
essential for enhancement of iNOS activity in macrophages,
thereby pointing to a proinflammatory role for eNOS .c.
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Growth Factor-Antagonized Rexinoid ApoptosisWe demonstrate here that, under conditions of growth factor
or serum limitation, RXR activation generates a strong and sus-
tained NO induction originating from both iNOS and eNOS.
Chromatin-IP experiments revealed PPARg and RXR binding
at 1 kb upstream of the iNOS TSS upon BMS749 treatment
(Figure 7F). Even though no apparent DR1-type PPRE was
found, this region harbors other DRs that could act as response
elements; whether these mediate the RXR-PPARg action in vivo
remains to be established. Although transcriptional activation of
iNOS is rapid, phosphorylation of eNOS occurs with a delay and
leads to a sustained response, suggesting a collaboration be-
tween the two types of NOS. A number of mechanisms have
been proposed to explain NO-mediated apoptosis through the
intrinsic pathway, such as ROS production, formation of perox-
ynitrite, and protein nitrosylation. Upon the exclusion of ROS, it is
possible that protein nitrosylation, peroxynitrite formation, which
leads to the opening of the mitochondrial transition pore, or inhi-
bition of cytochrome c oxidase play a critical role in NO-medi-
ated apoptosis (Beltran et al., 2000; Moncada and Erusalimsky,
2002).
To identify the point of convergence between growth factor
action and rexinoid apoptosis, we studied whether MAPK-
dependent phosphorylation of the RXR-PPARg heterodimer
could block apoptosis. Human RXRa can be phosphorylated
at S260 by ERK1/2, leading to impaired cofactor recruitment
and hormone insensitivity, while phosphorylation of PPARgS112
predisposes it to sumoylation at K107 and leads to strong trans-
repression that is absent in the K107R mutant. However, the
addition of serum still reduced the production of NO in cells
transfected with the PPARg mutants, suggesting that ERK1/2-
mediated repression of rexinoid apoptosis does not involve the
above PPARg modification. In contrast, transfection of the non-
phosphorylable mutant RXRaS260A abrogated the antiapopto-
genic serum effect on NO production, thus revealing that GFs
act via phosphorylation of RXRaS260 to protect cells from rexi-
noid apoptosis.
Growth factors play an essential role in cell survival. Serum
deprivation in culture media results in apoptosis, but growth
factors such as IGF1 and IGFII can support cell survival, at least
temporarily (Kurmasheva and Houghton, 2006). IL-3-dependent
hematopoietic cells can escape apoptosis in absence of IL-3
upon treatment with IGF, and such an effect has been extended
to such diverse cells as cortical neuronal cells, cerebral granule
cells, and a variety of malignant cells (Rodriguez-Tarduchy et al.,
1992). IGF can activate a number of antiapoptotic genes such
as Bcl-2 (Minshall et al., 1997) and induce phosphorylation of
BAD, a crucial regulator of mitochondrial apoptosis (Datta
et al., 1992). IGF effectively inhibits apoptosis by stress-inducing
agents such as ROS and NO in hippocampal neurons, and acti-
vation of AKT by IGF-I has been proposed as a central mecha-
nism for the inhibition of NO-induced apoptosis (Matsuzaki
et al., 1999). Blocking of IGF1 signaling has been demonstrated
in various in vivo models to inhibit tumor growth and enhances
the effects of established antitumor therapies (Clemmons,
2007). Thus, it could be intuited that inhibition of growth factor
signaling would leave cells particularly susceptible to apoptotic
signals. Indeed, sensitization of tumor cells to chemotherapeutic
agents by inhibition of growth factors with receptor antibodies or
small molecules against downstream signaling is now widelyCused to treat a variety of tumors (reviewed by Chitnis et al.,
2008; Clemmons, 2007; Wanebo et al., 2006). Together, these
studies tempted us to hypothesize that RXR, along with PPARg,
could control an endogenous default apoptotic pathway kept in
silent state by the action of growth factors.
The link between growth factor support and rexinoid apo-
ptosis prompted us to investigate a possible cancer therapeutic
potential of rexinoid apoptosis. It was particularly interesting that
a variety of cell types, both hematopoietic and solid cancer cell
lines, would undergo rexinoid apoptosis either in low serum or
under conditions where MAPK signaling is impaired (see
Figure 8). Interestingly, blocking GF support by combining the
MAPK inhibitor and IRESSA superactivated rexinoid apoptosis.
In one case, we could establish conditions for primary blasts
from a patient with AML that allowed us to demonstrate the
induction of rexinoid apoptosis, which was similar to that seen
with two prototypic HDAC inhibitors. A number of growth factor
signaling inhibitors, such as gefinitib and herceptin, have been
developed and are in therapeutic use as adjuvants to chemo-
therapy for the treatment of cancer. Several type 1 insulin-like
growth factor receptor (IGF1R) inhibitors (blocking antibodies
and tyrosine kinase inhibitors) are available, and at least 12 of
them are undergoing clinical trials as combinations with other
cancer treatments (Chitnis et al., 2008). Their combination with
RXR and/or PPARg agonists would be an attractive therapeutic
strategy. The mouse xenograft experiments described here con-
firmed the therapeutic potential of rexinoid apoptosis in vivo and
revealed the absence of any major toxicity. Interestingly, the
experiments demonstrated that even a general growth factor
signaling inhibitor such as U0126 can be highly effective in vivo
in combination with the RXR ligand BMS749. Recently, it has
been shown that combination of the PPARg agonist rosiglita-
zone with carboplatin significantly reduces the tumor burden in
drug-resistant non-small-cell lung cancer mouse model (Girnun
et al., 2007). Such a combination therapy would be particularly
attractive in cancers showing resistance to standard treatments.
Combination with specific inhibitors such as gefinitib (IRESSA)
would augment the selectivity of the treatment and thereby
reduce drug toxicity. Further studies in different models of carci-
nogenesis will be required to establish the full palette and gener-
ality of this principle and its therapeutic potential.
EXPERIMENTAL PROCEDURES
Ligands, Chemicals, and Antibodies
Sources and use of antibodies and chemicals are described in Supplemental
Data.
Cell Culture, Infection, and Transfection
PLB985, HCT116, MCF7, and HT29 were obtained from the in-house cell
culture service, and BJAB wild-type and BJAB DR5 KO cells were a kind gift
from Andrew Thorburn. PLB985 were adapted to minimal serum media and
were cultured in RPMI, 1% fetal calf serum, complemented with 1% HY (Bio-
sepra), gentamycin, 25 mM HEPES, and 2 mM glutamine. The Virapower len-
tiviral expression system (Invitrogen) was used to produce lentiviruses. Retro-
viruses were produced using pCLII ampho helper plasmid in BOSC23 cells.
HCT116 cells were transfected with different plasmids using Fugene 6 reagent
(Roche). PPARg2wt plasmid was obtained from C. Ronald Kahn via Addgene
(plasmid 11439). Site-directed mutagenesis was performed using the protocol
from Quickchange kit (Stratagene). p53 shRNA plasmid was obtained from
William Hahn via Addgene (plasmid 10672).ancer Cell 16, 220–231, September 8, 2009 ª2009 Elsevier Inc. 229
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PLB985 cells apoptosis was quantified by detection of the 7A6 mitochondrial
antigen (which is selectively exposed in cells undergoing apoptosis) using the
Apo2.7 antibody. Mitochondrial membrane potential was assayed by incu-
bating 2.5 3 105 cells with 50 nM DiOC6(3) for 30 min in the dark and subse-
quent examination by flow cytometry. NO production was quantified using
the selective DAF-FM diacetate probe at 5 mM concentration.
RNase Protection Assay
Total RNA was extracted with Trizol (Invitrogen-GIBCO BRL, Carlsbad, CA),
and RNase protection assays were performed according to the supplier’s
instructions (PharMingen, San Diego, CA).
p42/44 MAP Kinase Assay
p42/44 activity assay was measured in vitro, using the nonradioactive p42/44
MAP Kinase Assay Kit (Cell Signaling Technology) according to the manufac-
turer’s protocol using Elk-1 as substrate.
siRNA Studies
PLB cells were transfected with 50 pmoles of siRNA using Lipofectamine 2000
(Invitrogen) according to manufacturer’s protocol. Cells were used for analysis
after 36 hr incubation.
Chromatin Immunoprecipitation
Chromatin Immunoprecipitation (ChIP) was done according to standard
procedures. In brief, after treatment with ligands, HCT116 cells were cross-
linked with 1% paraformaldehyde for 30 min at room temperature. Cells
were scraped, sonicated, and then immunoprecipitated with RNA PolII
(sc-9001), PPARg (sc-7196) (Santa Cruz), and RXRa (in-house) antibodies
overnight. The recovery of the complexes, washing, de-cross-linking and
extraction of DNA was performed according to the Upstate protocol. Quanti-
tative real-time PCR was performed using sybr green mix from QIAGEN and
the primers mentioned in Supplemental Data.
In Vivo Experiments
Xenograft study using HCT116 colon carcinoma cell lines were performed in
Crl:Nu(Ico)Foxn1Nu mice (Swiss) mice (Charles River); 4 3 106 cells were in-
jected subcutaneously to the left flank. Treatments were started when the
tumors were approximately 4 mm. Animals were randomized in the treatment
groups, so that each group contains animals of approximately same size of
tumors before treatment. BMS749 (20 mg/kg bw) and U0126 (30 mg/kg bw)
were administered intraperitoneally for 2 weeks (11 doses, alternate days),
and tumor size was determined using Vernier Calliper measurement using
the following formula: tumor volume = (a2 3 b)/2, where a is width and b is
the length of the tumor. For in vivo imaging experiments, HCT116 cells stably
expressing firefly luciferase were used. In vivo imaging was performed after the
administration of luciferin (125 mg/kg bw) using a Xenogen IVIS 100 system
(Caliper Life Sciences). All animal studies were conducted following protocols
approved by the DDSV (Direction De´partementale des Services Ve´te´rinaires).
SUPPLEMENTAL DATA
Supplemental data include Supplemental Experimental Procedures and four
figures and may be found with this article online at http://www.cell.com/
cancer-cell/supplemental/S1535-6108(09)00252-9.
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